Brief: Galecto’S Gb0139 Shows Favorable Safety And Tolerability Profile With Promising Changes In Efficacy Markers In Hospitalized Covid-19 Patients

Damora Therapeutics

22/06/2021 15:59

June 22 (Reuters) - Galecto Inc  GLTO.O :
    * GALECTO’S GB0139 SHOWS FAVORABLE SAFETY AND TOLERABILITY
PROFILE
WITH PROMISING CHANGES IN EFFICACY MARKERS IN HOSPITALIZED
COVID-19 PATIENTS
    * GALECTO INC - DATA DEMONSTRATE POTENTIAL OF GB0139 IN
PATIENTS
WITH VIRAL-INDUCED ACUTE LUNG INJURY
    * GALECTO INC - CURRENTLY GALECTO WILL PRIORITIZE RESOURCES
FOR
ITS FOUR PHASE 2 TRIALS IN FIBROSIS AND CANCER
    * GALECTO INC - GB0139 SIGNIFICANTLY REDUCED OXYGEN FLOW
REQUIREMENTS AND IMPROVED SEVERAL BIOMARKERS FOR LUNG AND
SYSTEMIC INFLAMMATION, LIVER FUNCTION

Source text for Eikon:  ID:nGNX5XDvgB 
Further company coverage:  GLTO.O 

 ((Reuters.Briefs@thomsonreuters.com;))